ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

Phase 1/2 Recruiting 12 enrolled Eureka Therapeutics Inc.

NaSingle-groupOpen-labelTreatment

Summary

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

Timeline

Start: 2022-07-19
Primary completion: 2027-12-31
Completion: 2028-01-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Biological/Vaccine: ET140203 autologous T-cell product Autologous T cells transduced with lentivirus encoding an ET140203 expression construct	Cell therapy	—	Intravenous

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

Summary

Timeline

Drugs

Indications